Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down

Eli Lilly shares plummeted 14% after late-stage trial data for its oral obesity drug, orforglipron, showed patients without diabetes lost just over 12% of body weight, falling short of analyst expectations for 15% and trailing competitor Novo Nordisk's oral Wegovy. This significant decline, the steepest for LLY since 2000, underscores high investor expectations and intense competition in the lucrative weight-loss market. The news simultaneously boosted Novo Nordisk shares, highlighting the direct market rivalry as Lilly plans regulatory filing by year-end.

Analysis

Eli Lilly (LLY) experienced its most significant single-day stock decline since 2000, plummeting 14% after late-stage trial data for its oral obesity drug, orforglipron, failed to meet investor expectations. The drug demonstrated just over 12% weight loss in non-diabetic patients, falling short of the 15% consensus analyst forecast and, more critically, trailing the 15% efficacy reported for Novo Nordisk's (NVO) competing oral therapy. This efficacy gap triggered a sharp market repricing, with NVO shares simultaneously surging over 7%, highlighting the direct and intense competition in the lucrative weight-loss market. Despite the market's verdict, Eli Lilly's CEO stated the results were "right on thesis," suggesting a disconnect between internal goals and Wall Street's high expectations, which had been bolstered by previously successful trial data in diabetic patients. The company still intends to file for regulatory approval by the end of the year, signaling its belief in the drug's commercial viability, though it now faces a more challenging competitive landscape against a rival with superior reported data.

Key Decisions for Investors

• Investors should re-evaluate valuation models for Eli Lilly, as the disappointing orforglipron data suggests a potentially smaller market share and weaker competitive positioning against Novo Nordisk in the oral obesity segment.
• The data reinforces Novo Nordisk's leadership position, potentially justifying a premium for NVO stock as its oral treatment now appears to have a superior efficacy profile ahead of its expected FDA decision in 2025.
• Monitor Eli Lilly's regulatory filing by year-end, as the details and subsequent FDA interactions will be critical catalysts in determining orforglipron's ultimate commercial viability and market acceptance.